Key Highlights

  • Revenue grew 49% year over year to USD 890 million.
  • Adjusted EBITDA was USD 82 million, a 9% margin.
  • Subscribers grew 13% to 2.8 million.
  • International Revenue was USD 233 million, including about USD 135 million from Eucalyptus.

Hims & Hers Health, Inc. (NYSE:HIMS) reported third quarter 2026 revenue of USD 890 million, up 49% year over year, the second consecutive quarter of accelerating revenue growth. Reported EPS was negative USD 0.14 and revenue was USD 890.37 million, compared with estimates of EPS of USD 0.06 and revenue of USD 892.88 million.

Revenue excluded USD 18 million from the scaling of membership revenue in the weight loss offering, which is deferred and recognized in the fourth quarter. GAAP Net Income was a loss of USD 33 million. Adjusted EBITDA grew 37% quarter over quarter to USD 82 million, a 9% margin, and also did not reflect the USD 18 million of deferred revenue.

Subscribers and Domestic Revenue

Subscribers grew 13% year over year to 2.8 million but declined sequentially by 100,000 net subscribers, which management tied to measured Marketing spend in the domestic weight loss specialty and Brand migrations in international markets. Domestic revenue growth accelerated for the second consecutive quarter to 21%, with U.S. operations generating USD 657 million of revenue, compared with 16% growth in the second quarter.

International and Specialties

International revenue more than quadrupled to USD 233 million, including an approximately USD 135 million contribution from Eucalyptus, with the remaining portion of the international portfolio growing nearly 80%. Management cited international revenue passing a USD 1 billion run rate in 2027.

Hers continues to progress toward USD 1 billion of revenue this year as dermatology and menopause scale alongside weight loss. Testosterone is progressing toward a USD 100 million annualized revenue run rate, supported by the launch of injectable solutions last month. Through a recently announced agreement, the company is expanding access to Lilly's GLP-1 medications, Zepbound and Foundayo. It also named TB-500 and BPC-157, manufactured and compounded in the U.S., as offerings to follow.

Management said the company owns more than 1 million square feet of pharmacy, lab and compounding infrastructure and that nearly 3 million people across four continents rely on it to access care. Its long term strategy rests on three commitments, the first being to win metabolic health in the U.S.

The AI native experience reaches 70% of weight loss subscribers as of quarter end, with nearly 100% cited before year end. Customers with access to the new experience send four times as many messages on the platform. Management said it has intentionally pulled back on marketing spend in the weight loss Business following structural changes over recent quarters, to prepare for the new year and to create flexibility to invest behind new specialties and offerings.

Margins, Costs and Cash

Gross margins were 57% in the third quarter, down approximately 7 points on a quarter over quarter basis. Investment in technology, talent and platform represented 8% of revenue. Marketing as a percentage of revenue improved 7 points quarter over quarter to 28%, operations and support costs improved 1 point to 12% of revenue, and G&A expenses improved 5 points on a GAAP basis to 17%.

Cash flow from operations was USD 65 million and free Cash Flow was USD 26 million in the third quarter. The company reported over USD 710 million of cash and investments at the end of the quarter. The Hers 2.0 app launched last quarter.

Where the Company Placed Its Focus

Management framed the quarter around three areas: the AI native experience, which reaches 70% of weight loss subscribers, the expansion of specialties such as dermatology, menopause and testosterone, and growth in international markets, where Eucalyptus contributed approximately USD 135 million. The company also pointed to its agreement to expand access to Lilly's GLP-1 medications, Zepbound and Foundayo, and to its more than 1 million square feet of owned pharmacy, lab and compounding infrastructure. It closed the quarter with over USD 710 million of cash and investments and reported USD 65 million of cash flow from operations.